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sequent fibrosis. While inflammatory cytokines, including interleukin (IL)-6,
are elevated in IPF, the molecular mechanisms that underlie this disease are
incompletely understood, although the development of fibrosis is believed to
depend on canonical transforming growth factor (TGF)-b signalling. We
examined bleomycin-induced inflammation and fibrosis in mice carrying a
mutation in the shared IL-6 family receptor gp130. Using genetic complementa-
tion, we directly correlate the extent of IL-6-mediated, excessive Stat3 activity
with inflammatory infiltrates in the lung and the severity of fibrosis in
corresponding gp130757F mice. The extent of fibrosis was attenuated in B
lymphocyte-deficient gp130757F;mMT/ compound mutant mice, but fibrosis
still occurred in their Smad3/ counterparts consistent with the capacity of
excessive Stat3 activity to induce collagen 1a1 gene transcription independently
of canonical TGF-b/Smad3 signalling. These findings are of therapeutic
relevance, since we confirmed abundant STAT3 activation in fibrotic lungs from
IPF patients and showed that genetic reduction of Stat3 protected mice from
bleomycin-induced lung fibrosis.– Parkville Branch,
, School of Medicine
, Nedlands, Western
rn Australia, Australia
ersity of Melbourne,
itute, Vancouver, BC,
McMaster University,
a
Melbourne, Victoria,
(9) Telethon Institute for Child Health Research, Centre for Child Health
Research, University of Western Australia, Western Australia, Australia
(10) Centre for Respiratory Research, Rayne Institute, Royal Free and
University College London, London, UK
(11) Department of Biochemistry, Christian-Albrechts-Universita¨t zu Kiel,
Kiel, Germany
(12) PathWest Laboratory Medicine WA, Nedlands, Western Australia,
Australia
*Corresponding author: Tel: þ61 3 9341 3155; Fax: þ61 3 9341 3104;
E-mail: matthias.ernst@ludwig.edu.au
**Corresponding author: Tel: þ61 8 9346 7948; Fax: þ61 8 9346 4159;
E-mail: mutsaers@liwa.uwa.edu.au
yThese authors contributed equally to this work.
Ltd on behalf of EMBO. This is an open access article under
ercial License, which permits use, distribution and
s properly cited. EMBO Mol Med (2012) 4, 939–951 939
Research Article www.embomolmed.org
Stat3 mediates lung fibrosis independent of Smad3
940INTRODUCTION
Tissue fibrosis results from excessive and progressive scarring
associated with destruction of normal tissue architecture and
structure, and ultimately compromises organ function (Wilson
& Wynn, 2009; Wynn, 2007). The clinical challenge of treating
fibrotic diseases is exemplified by idiopathic pulmonary fibrosis
(IPF), a heterogeneous disease unresponsive to therapy and
fatal in outcome (Knight et al, 2003; Wilson & Wynn, 2009).
Although the molecular mechanisms underlying initiation of
IPF remain largely unknown, fibrosis is thought to arise from
excessive tissue response to injury. Accordingly, effort has
concentrated on the genetic dissection of steps that collectively
govern normal wound healing processes and that enable re-
epithelialization and extracellular matrix production to subside
upon re-establishment of tissue homeostasis. Besides epithelial
proliferation, differentiation and regeneration, these processes
also involve stromal components, which are activated as part of
the ensuing inflammatory response (Wilson & Wynn, 2009).
In IPF, epithelial injury is followed by pathologic fibrotic
repair in distinct cellular foci within the lung parenchyma
comprising proliferating fibroblasts and subepithelial myofi-
broblasts that are associated with excessive deposition of
extracellular matrix proteins, including type I collagen (Cool
et al, 2006; Maher et al, 2010; Moodley et al, 2003). Activation
of these myofibroblasts correlates with increased levels of
interleukin (IL)-1b, IL-4, IL-13, IL-17, and other inflammatory
cytokines and is believed to be mediated by transforming
growth factor (TGF)-b (Wilson & Wynn, 2009; Wilson et al,
2009). TGF-b and its canonical downstream signalling molecule
Smad3 are central to the development and progression of
fibrosis as elevated levels of TGF-b are sufficient to reproduce
organ fibrosis in animal models, stimulate fibroblast differ-
entiation and epithelial-to-mesenchymal transformation, and
the observation that Smad3-deficiency confers resistance in
mouse models of IPF (Bonniaud et al, 2004; Zhao et al, 2002).
During inflammation, stromal cells and those of the
macrophage/monocyte lineage release inflammatory cytokines
of the IL-6 family, which are thought to promote fibrosis through
Erk1/2 signalling-associated fibroblast proliferation (Moodley et
al, 2003) and the induction of a fibrotic response that ismediated
by various TGF-b family of ligands (Ogata et al, 2006). Several
members of the IL-6 cytokine family, which is characterized by
the shared use of the common gp130 receptor subunit, have
been implicated in pulmonary fibrosis. Transgenic overexpres-
sion of IL-11 or Oncostatin M (Osm) in mice, for instance,
promotes lung scarring with striking histo-pathological simila-
rities to that observed in human disease (Bamber et al, 1998;
Kuhn et al, 2000). Meanwhile, overexpression of IL-6 is a
common finding in bronchoalveolar lavage (BAL) fluid of IPF
patients (Mozaffarian et al, 2008), where IL6 gene polymorph-
isms segregate with disease severity (Pantelidis et al, 2001).
Meanwhile, activation of the latent transcription factor Stat3,
one of the signalling molecules engaged by gp130, has been
proposed to affect fibrosis in skin and liver (Ghazizadeh et al,
2007; Ogata et al, 2006), albeit with contradicting outcomes
(Mair et al, 2010). These observations therefore leave the 2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.mechanisms unresolved by which the wide-spread expression
of gp130 on epithelial, stromal and hematopoietic cells, and the
individual intracellular molecular components engaged by
gp130 contribute to fibrosis and whether this response requires
canonical TGF-b/Smad3 signalling (Knight et al, 2003).
In this study, we use gp130 mutant mice with either
deregulated Stat1/3 or Erk1/2-signalling to assess susceptibility
to bleomycin administration as a widely used model that
recapitulates epithelial injury-induced lung fibrosis (Moeller et
al, 2008). We found that ligand-dependent excessive Stat1/3
activation, either in the hematopoietic or stromal compartments
of gp130757F mice (Jenkins et al, 2005a), increased bleomycin-
induced fibrosis in an IL-6 dependent manner, and that systemic
ablation of Il6 or impairment of gp130-mediated Stat3 activa-
tion, attenuated the fibrotic response. Importantly, gp130-
mediated lung fibrosis occurred independently of canonical
TGF-b signalling in Smad3-deficient mice, but required mature
B lymphocytes and correlated with parenchymal accumulation
of B-cell containing foci. With the prevalence of excessive Stat3
activation in lungs of IPF patients and the capability of
therapeutically targeting components of the gp130 signalling
cascade, our findings are likely to be of clinical relevance.RESULTS
Excessive fibrotic response in mice with exaggerated
IL-6-dependent Stat3 hyperactivation
To mimic the development of human inflammation-associated
lung fibrosis in mice, we trans-nasally administered bleomycin
to gender-matched mice (8–12 weeks of age) harbouring gp130
mutations that bias intracellular signalling either towards the
Stat1/3 or Erk1/2 signalling pathways in gp130757F mice or
gp130DStat mice, respectively (Tebbutt et al, 2002) (Supporting
Information Fig S1). Compared to wild-type (gp130wt) mice,
bleomycin-challenged gp130757F mice showed extensive
changes to their lung architecture, including consolidation of
airspaces, thickened alveolar septae, inflammation and epithe-
lial dysplasia (Fig 1). In contrast, gp130DStat mice were
completely protected from pulmonary fibrosis. We corroborated
these observations by measuring hydroxyproline content of
lungs as an established marker of collagen deposition 14 and
30 days following bleomycin challenge, as well as by assessing
Col1a1 transcription in lungs of these mice (Fig 2A and B). We
have previously shown that gp130DStat, gp130wt and gp130757F
mice simultaneously comprise an allelic series for increasing
gp130-mediated Stat1/3 signalling (attenuated in gp130DStat
and excessive in gp130757F mice) and for Erk1/2 signalling
(excessive in gp130DStat and attenuated in gp130757F mice)
(Jenkins et al, 2005a; Tebbutt et al, 2002). This was confirmed
by examining the abundance of transcriptionally active, tyrosine
phosphorylated form of Stat3 (pStat3) in lung fibroblasts
obtained from gp130757F, gp130wt and gp130DStat mice treated
with IL-6 for 0–180min (Supporting Information Fig S2A). The
molecular rationale underpinning the reciprocal relationship
between activation of the Stat1/3 and Erk1/2 signalling arises
from the observation that the negative regulatory Socs3 proteinEMBO Mol Med (2012) 4, 939–951
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Figure 1. Gp130 cytokine family-mediated Stat3
signalling determines susceptibility to fibrosis.
Masson’s trichrome stain of lungs from gp130wt (wt),
gp130757F (757F), gp130DStat (DStat) or
gp130757F;Stat3þ/ (757F;Stat3þ/) mice 30 days
after saline or bleomycin treatment. Images are
representative of threemice for each genotype. Scale
bar¼ 500mm (¼100mm insets).is transcriptionally induced by Stat3 and requires binding to
the phosphorylated tyrosine residue in position 757 in mouse
(759 in human) gp130 (Ernst & Jenkins, 2004).
In order to dissect the contribution of the individual pathways
engaged by gp130 to the fibrotic response, we systemically
restricted the pool of Stat3 or Stat1 available for activation using
compound gp130757F mice (Ernst et al, 2008). Upon reduction
of excessive Stat3 activation observed in compound
gp130757F mice to levels more comparable to those observed
in gp130wtmice, we detected a similar fibrotic response between
gp130757F;Stat3þ/ and gp130wt mice 30 days after challenge
(Figs 1 and 2A,B). However, complete Stat1 ablation inEMBO Mol Med (2012) 4, 939–951gp130757F;Stat1/ mice only provided partial protection from
fibrosis (Supporting Information Fig S2B and C). These genetic
observations imply that the enhanced fibrosis observed in
gp130757F mice mediated by increased Stat3 activation exceeds
that mediated by genetic ablation of Stat1 expression (Walters
et al, 2005) and suggest a direct relationship between the
severity of the fibrotic response and the extent of gp130-
mediated Stat3 signalling. Consistent with this, we detected
excessive Col1a1 luciferase (Col1a1-luc) reporter activity in
gp130757F embryonic fibroblasts in response to stimulation with
the pan-gp130 designer cytokine HYPER-IL-6 (Fig 2C). Since
HYPER-IL-6 activates gp130 independently of the ligand binding 2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 941
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Figure 2. Gp130-mediated Stat3 signalling stimulates collagen accumulation and collagen transcription.
A. Percent change in collagen content in lung homogenates between saline and bleomycin-treated wild-type (wt), gp130757F (757F), gp130DStat (DStat) and
gp130757F;Stat3þ/ (757F;Stat3þ/) mice 14 and 30 days after bleomycin challenge. Data were normalized to mean collagen content of syngeneic saline
controls and expressed as percentage change. n 4 mice. The range of collagen between saline and bleomycin treated mice was 3.219–44.710mg.
B. qPCR analysis of Col1a1 mRNA expression in lung homogenates 30 days after bleomycin treatment and normalized to Gapdh expression. n¼4 mice.
C. HYPER-IL-6-dependent stimulation of Col1a1-luc reporter activity in transiently transfected embryonic fibroblasts. Data were normalized to Renilla luciferase
activity and expressed as the relative change in relative luminescence units (RLU) compared to untreated syngeneic cells. n¼ 3 mice.
D. qPCR analysis of Il6mRNA expression in lung homogenates frommice 3, 14 and 30 days after and before bleomycin challenge and control mice (0). n¼ 4mice.
E. qPCR analysis of Col1a1mRNA expression in lung homogenates following 2 weeks of trans-nasal HYPER-IL-6 delivery. Col1a1 signals are expressed relative to
the Col1a1/18S ratio of HYPER-IL-6 challenged wt mice. n¼4 mice. All data are expressed as mean SEM with p<0.05, p< 0.01 using Bonferroni multiple
comparisons test.
942IL-6 receptor a-subunit (Fischer et al, 1997), this excludes the
possibility that our observed results reflect potential differences
in endogenous IL6 receptor expression between the different
genotypes. We measured mRNA levels of the IL-6 family
members Il6, Il11 andOsm in the lungs of wt and gp130757Fmice
3 days after bleomycin challenge and found that in bleomycin-
challenged lungs of gp130757F mice, Il6 mRNA remained 2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.selectively elevated 14 days later (Fig 2D and Supporting
Information Fig 2D). Trans-nasal administration of HYPER-IL-6
promoted Col1a1 gene transcription profoundly in lungs of
gp130757Fmice relative to lungs of gp130757F;Stat3þ/ or gp130wt
mice (Fig 2E). The potential role of IL-6 family molecules
directly promoting lung fibrosis was further supported by our
observation that genetic ablation of Il6 in gp130757F;Il6/ miceEMBO Mol Med (2012) 4, 939–951
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bleomycin challenged gp130757F mice (Supporting Information
Fig S3A and B).
Excessive fibrotic response in gp130757F mice depends on
mature B lymphocytes
Injury-dependent induction of cytokines primes the subsequent
inflammatory response that precedes the development of
pulmonary fibrosis (Wilson & Wynn, 2009). We therefore
analysed BAL fluid from bleomycin-challenged mice and
observed augmented cytokine accumulation, in particular of
IL-1, IL-6, IL-13, and GCSF, in gp130757Fmice when compared to
gp130wt, gp130757F;Stat3þ/, or gp130DStat mice (Supporting
Information Fig S4A and B). However, at the height of theFigure 3. Increased lymphocytes are associated with inflammation and lung
A. Changes to cell numbers in BAL fluid of wild-type (wt), gp130757F (757F), gp1
bleomycin administration relative to saline-treated mice of the same genotyp
lymphocytes.
B. Distribution of inflammatory cells in foci within the lung parenchyma of mice
appearance (PMN) or immunohistochemical staining for F4/80 (MØ), or CD3
C. Female wt or 757Fmice (n>3 per group) were reconstitutedwith bonemarrow
bleomycin or saline administration. Bars indicate percent change in collagen c
range of collagen between saline and bleomycin treated mice was 7.089–31.65
have not undergone bone marrow transplant.
D. qPCR analysis of Col1a1 mRNA expression in lung homogenates 30 days afte
gp130757F;mMT/ (757F;mMT/) mice. Col1a1 signals were normalized to 18
mice. All data are expressed as mean SEM with p< 0.05, p<0.01 and 
EMBO Mol Med (2012) 4, 939–951inflammatory response 3 days after bleomycin administration
(Moeller et al, 2008; Wilson & Wynn, 2009), there was no
correlation between the number of inflammatory cells contained
within BAL fluid of bleomycin-challenged mice (Fig 3A and
Supporting Information Fig 4C) and extent of fibrosis 30 days
later (Figs 1 and 2A and Supporting Information Fig 3A and B).
Foci of inflammatory cells within the lung parenchyma
were most prominent in gp130757F mice compared to all other
genotypes of mice consistent with the severe fibrosis observed
in these mice (Fig 3B and Supporting Information Fig S5A).
Collectively, these data suggest that attenuated Stat3 activation
may enable egression of inflammatory cells into BAL fluid, while
excessive Stat3 activity may promote their retention in the lung
parenchyma.fibrosis.
30DStat (DStat) and gp130757F;Stat3þ/ (757F;Stat3þ/) mice 3 days after
e. n4 mice. MØ, macrophages; PMN, polymorphonuclear cells and LYM,
3 days after bleomycin treatment. Cell types were identified by histological
and B220 (LYM). n4 mice.
from 757F, wt orDStatmice and lungs were collected challenged 21 days after
ontent in lung homogenates between saline and bleomycin treated mice. The
8mg. Empty bars show lung collagen levels in bleomycin challenged mice that
r bleomycin challenge of wt, 757F, gp130757F;Rag1/ (757F;Rag1/) and
S and expressed relative to saline-treated mice of the same genotype. n¼4
p< 0.001 using Bonferroni multiple comparisons test.
 2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 943
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944Since bleomycin-induced lung fibrosis depends on the
preceding inflammatory response (Moeller et al, 2008), we
performed adoptive bone marrow transfer experiments to
compare the contributions to disease between the hematopoietic
and the parenchymal compartment. We excluded a major
effect from the irradiation process, since the fibrotic response
remained indistinguishable between non-irradiated and non-
reconstituted bleomycin challenged gp130757F or gp130wt mice
and their syngeneically reconstituted counterparts (Fig 3C).
However, in reconstituted gp130757F hosts, but not in gp130wt
hosts, we observed a gradual attenuation of bleomycin-induced
hydroxyproline accumulation that correlated with the extent by
which gp130-dependent Stat3 activation could occur in donor
cells (i.e. excessive in gp130757F and attenuated in gp130DStat
bone marrow cells). Furthermore, when reconstituted with
bone marrow proficient for gp130-dependent Stat3 signalling
(i.e. gp130757F or gp130wt cells), gp130757F hosts were more
susceptible to fibrosis than gp130wt hosts. Collectively, these
observations suggest that excessive gp130-mediated Stat3
signalling in the lung parenchyma of gp130757F hosts promotes
fibrosis, which is further amplified by excessive Stat3 signalling
in bone marrow-derived cells.
The striking correlation between focal lymphocytic accumu-
lation in the lung parenchyma of gp130757Fmice and the severity
of their fibrotic response (Figs 2A and 3B) is consistent with a
role for lymphocytes during development of bleomycin-induced
lung fibrosis and their prominent abundance in fibrotic
tissues of IPF patients with non-specific interstitial pneumonia
(Keogh & Limper, 2005; Wilson & Wynn, 2009). Indeed,
we observed a profound increase in B220-positive cells
in bleomycin-challenged gp130757F mice, which persisted for
30 days (Supporting Information Fig S5B and C). Furthermore,
mature lymphocytes exacerbate fibrosis in gp130757F mice,
since fibrosis in T and B lymphocyte compound-deficient
gp130757F;Rag1/ mice was reduced and comparable to
disease in bleomycin challenged wild-type mice (Supporting
Information Fig S5D). This observation was corroborated at the
level of Col1a1 gene transcription which was similar in wild-
type and gp130757F;Rag1/ mice (Fig 3D). Moreover, we also
observed reduced fibrosis and collagen transcription in
gp130757F;mMT/ compound mutant mice deficient in mature
B lymphocytes. Collectively, our findings suggest that bone
marrow derived B lymphocytes promote bleomycin-induced
fibrosis in susceptible gp130757F hosts (Fig 3D and Supporting
Information Fig S5D).
TGF-b response is blunted in gp130757F mice
The development of experimental fibrosis correlates with
elevated TGF-b levels, which is thought to molecularly link
the activity of inflammatory cytokines to the resulting fibrotic
response (Bonniaud et al, 2005; Gauldie et al, 2007). This
concept is supported by the observation that two distinct Smad3
null mutations protect mice from bleomycin-induced lung
fibrosis (Bonniaud et al, 2004; Zhao et al, 2002) as well as TGF-
b-induced lung fibrosis (Bonniaud et al, 2004; Bonniaud et al,
2005). Using recombinant TGF-b1 as a reference, we detected
elevated levels of TGF-b activity in serum from gp130757F mice 2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.when assayed on NIH3T3 cells expressing the pCAGA12-luc
reporter plasmid that records Smad3-dependent gene
transcription (Supporting Information Fig S6A). However,
when assaying for TGF-b-induced phosphorylation of Smad3
(pSmad3) we observed reduced abundance of this transcrip-
tionally active form of Smad3 in lung fibroblasts from gp130757F
mice compared to those prepared from gp130wt, gp130DStat or
gp130757F;Stat3þ/ mice (Supporting Information Fig S6B).
Similarly, the capacity of TGF-b to induce Col1a1 gene
expression was reduced in lung fibroblasts from gp130757F
mice when compared to those obtained from either gp130wt or
gp130757F;Stat3þ/ mice (Supporting Information Fig S6C),
suggesting that excessive Stat3 activation decreases TGF-b-
responsiveness of primary lung fibroblast from gp130757F mice.
Indeed, this observation is consistent with our previous findings
that excessive Stat3 activity blunted TGF-b-induced signalling
(i.e. Smad2 phosphorylation) and transcriptional response (i.e.
pCAGA12-luc activity) in mouse embryo fibroblasts and gastric
epithelium of gp130757F mice due to enhanced transcriptional
induction of the TGF-b signalling antagonist Smad7 (Jenkins
et al, 2005a).
Fibrosis in gp130757F mice occurs independently of Smad3
Since gp130757F mice develop a more profound fibrotic
response to bleomycin despite their attenuated TGF-b
responsiveness, we next determined genetically whether their
enhanced lung fibrosis could occur independently of canonical
TGF-b signalling. We therefore challenged gp130757F and
gp130757F;Smad3/mice with bleomycin and observed 21 days
later in both genotypes of mice a profound fibrotic response
that was characterized by excessive hydroxyproline accumula-
tion and collagen deposition in the pulmonary interstitium
(Fig 4A and B). In gp130wt mice, however, ablation of Smad3
(Smad3/) reduced bleomycin-dependent lung fibrosis in mice
as previously reported (Bonniaud et al, 2004; Zhao et al, 2002)
when compared to the fibrotic lesions and excessive collagen
deposition observed in Smad3 proficient wild-type mice 30 days
after bleomycin challenge (Fig 4A and B).
To ascertain that excessive Stat3 activation could mediate
bleomycin-induced fibrosis independently of Smad3, we
extended this observation to a physiologically more relevant
setting where excessive Stat3 signalling occurred in gp130wt
mice in response to prolonged exposure to gp130 cytokines
rather than through engagement of mutant gp130757F receptors.
Since prolonged exposure of mice to Osm and other gp130-
cytokines promotes excessive collagen production and fibro-
blast proliferation (Mozaffarian et al, 2008; Scaffidi et al, 2002),
we transnasally administered a replication-deficient adenovirus
encoding murine Osm to wild-type mice and demonstrated
an increase in transcriptionally active phosphorylated Stat3
(Supporting Information Fig S6D). Furthermore, continuous
exposure of Smad3/ mice to Osm induced severe sub-
epithelial and interstitial pulmonary fibrosis 14 days later
that was comparable to the response seen in wild-type mice
(Fig 4C). This was in contrast to Smad3 deficiency conferring
protection from bleomycin-induced lung fibrosis in gp130wt
mice (Fig 4A and B).EMBO Mol Med (2012) 4, 939–951
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Figure 4. Stat3 promotes lung fibrosis and collagen synthesis independent of Smad3.
A. Masson’s trichrome stained sections of lung from gp130wt (wt), Smad3/ (Smad3/), gp130757F (757F) or gp130757F;Smad3/ (757F;Smad3/) mice
21 days after challenge with bleomycin or saline. Images are representative of n¼ 3 mice. Scale bar¼500mm (¼ 100mm insets).
B. Percent change in collagen content in lung homogenates between saline and bleomycin treated mice of the indicated genotypes 30 days after challenge. n3
mice. The range of collagen levels between saline and bleomycin treated mice was 4.369–26.48mg. Data are expressed as mean percentage change SEM,
with p< 0.05 using Bonferroni multiple comparisons test.
C. Masson’s trichrome stained section of lungs from wt (top) or Smad3/ (bottom) mice 14 days after trans-nasal delivery of control (left) or Ad-mOsm virus
(right). Images are representative of three mice. Scale bar¼500mm (¼ 100mm insets).Excessive STAT3 phosphorylation in human IPF tissue
To explore the potential relevance of our findings in the
gp130757F mouse model to human IPF, we first confirmed
that excessive Stat3 activation in fibrotic lungs of bleomycin
challenged gp130757Fmice was dependent on IL-6 bymonitoring
expression of the bona fide Stat3 target gene Socs3 (Kidder et al,
2008; Snyder et al, 2008). While we observed an IL-6-
independent transient increase in Socs3 expression 3 days after
the bleomycin challenge (Fig 5A), Socs3 expression remained
elevated up to 30 days only in IL-6-proficient gp130757F mice
if Stat3 expression was not genetically depleted (i.e. in
gp130757F;Stat3þ/ mice). These observations correlated with
our findings of accumulation of phosphorylated Stat3 within
cells that collectively comprise the fibrotic areas of eitherEMBO Mol Med (2012) 4, 939–951bleomycin-challenged gp130757F or gp130wt mice, which also
extended to cells immediately adjacent to the collagenous
deposits (Fig 5B). Next, we retrospectively investigated
STAT3 activation in lung sections from IPF patients that were
clinically diagnosed with usual interstitial pneumonia (IPF-UIP,
Supporting Information Table T1). Since we detected pro-
nounced pSTAT3 staining in the parenchymal cells adjacent to
collagenous foci in these biopsies (Fig 5C), we categorized these
cells by concordant immunoreactivity for pan-cytokeratin
or CD45 as being of epithelial and haematopoietic origin,
respectively. This analysis revealed pSTAT3 nuclear staining in
cells co-expressing pan-cytokeratin in addition to extensive
regions of cells with nuclear pSTAT3 staining that was
discordant with cells staining for pan-cytokeratin or CD45 2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 945
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Figure 5.
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3(Fig 5D). These observations are consistent with emerging
reports suggesting that STAT3 activation not only occurs within
inflammatory cells associated with fibrotic lesions (Lim et al,
2006; Lim et al, 2009; Ogata et al, 2006), but also may play a
role in non-epithelial cells to exacerbate the wound-healing
responses that are characteristic for IPF lesions.
Genetic restriction of Stat3 signalling ameliorates the fibrotic
response in bleomycin-challenged mice
The potential role of excessive gp130-mediated STAT3 signal-
ling in human IPF prompted us to explore whether reduction of
Stat3 could confer a prophylactic protection from lung fibrosis.
To this end, we reasoned that future therapeutic interventions
may confer a systemic rather than lung-specific effect on Stat3
activation. We therefore mimicked this situation by testing
the susceptibility of Stat3þ/ mice to bleomycin-induced lung
fibrosis. Surprisingly, Stat3þ/ mice were completely protected
from the fibrotic response and associated deposition of collagen
in the lung when compared to wild-type mice (Fig 6A and B).
Indeed, the prophylactic effect afforded by genetic restriction of
Stat3 expressionwasmore effective than complete gene ablation
of IL-6 in mice, which only resulted in partial attenuation of the
severity of bleomycin-induced fibrosis (Fig 6A and B; Saito et al,
2008). These findings suggest that in addition to IL-6, other
gp130 cytokine family members may contribute to the fibrotic
response and therefore systemic inhibition of gp130/Stat3
signalling may provide additional benefits that are not afforded
through targeting of a single cytokine only.DISCUSSION
Although a timely resolution of acute inflammation in response
to (bleomycin-induced) injury enables restoration of normal
tissue architecture, an unrelenting inflammatory response
undermines the healing process and culminates in tissue
fibrosis (Wilson & Wynn, 2009; Wynn, 2007). Previous studies
have attempted to experimentally replicate excessive inflamma-
tion by overexpressing inflammatory cytokines including TNF-a
or IL-1b (Kolb et al, 2001; Sime et al, 1998). Here, we provide a
model where the increased sensitivity of mutant gp130757F
receptors mediates cytokine-dependent Stat3 activation in mice
akin to a smouldering asymptomatic inflammation triggered
by prolonged intranasal administration of Osm to wild-type
mice or excessive abundance of IL-6 or OSM associated with theFigure 5. Lung fibrosis is associated with activation of gp130-Stat3 signallin
A. qPCR analysis of Socs3mRNA expression in lung homogenates from gp130wt
(757F;Stat3þ/) mice 3, 14 and 30 days after bleomycin challenge or from co
saline-treated mice of the same genotype. n3 mice. Data are expressed
comparisons test.
B, C. Adjacent lung sections stained either with Masson’s trichrome or phosphor
bleomycin challenge (B), or from IPF patients diagnosedwith usual interstitia
in the bottom panels showing immunoreactive pStat3 staining associated w
respectively. Scale bar¼100mm (top and middle panels), ¼20mm (bottom
D. Haematoxylin and eosin (H&E) stained and dual fluorescence immunohisto
respectively, in lung sections from IPF-UIP patients. Scale bar¼100mm (H
EMBO Mol Med (2012) 4, 939–951pathogenesis of fibrosis in IPF patients (Lesur et al, 1994;
Mozaffarian et al, 2008; Xing et al, 1994).
While the exact mechanism of action by which excessive
Stat3 activation promotes fibrosis remains to be further
elucidated, our observation in bone-marrow reconstituted
mice indicates a shared contribution of non-haematopoietic
(most likely pulmonary epithelium and fibroblast) and
haematopoietic cells types. Furthermore, our data also suggests
that excessive Stat3 activation promotes tissue retention of
innate immune cells and increases the numbers of immature and
mature lymphocytes in gp130757F mice (Jenkins et al, 2005b).
Consistent with this, others have reported that blocking the
interaction between the Stat3 target gene Icam-1 and lympho-
cytes decreased lymphocyte retention in the normal pulmonary
vasculature (Klemm et al, 2000). Although IL6 is a well
characterized inflammatory target gene for TNF-a, and
bleomycin-induced fibrosis is ameliorated in Tnfr/ mice
(Ortiz et al, 1998), B cell infiltrates also fuel IL-6-mediated
and Stat3-dependent cancer growth following the release
of lymphotoxin (LT) (Ammirante et al, 2010). Intriguingly,
bleomycin-induced fibrosis is not only prevented in
Tnf/;Lta/ mice (Piguet et al, 1997), but also depends on
the presence of CD19-positive B-cells in wild-typemice (Komura
et al, 2008). Consistent with these observations, we provide
here genetic evidence that the bleomycin-induced fibrotic
response in gp130757F mice requires mature B lymphocytes.
This correlates with exacerbated accumulation of B220þ cells
and with enhanced abundance of the Th2 cytokine IL-13 in the
lung, which in itself not only requires Stat3 for its effective
production (Stritesky et al, 2011), but also promotes fibrosis
(Fichtner-Feigl et al, 2006). It is therefore tempting to speculate
that, for instance, the combined activity of LT and TNF-a,
through induction of gp130-activating cytokines, indirectly
promotes Stat3 signalling and the excessive matrix production
that underpins lung fibrosis. This view is consistent with
observations that the lower respiratory tract of IPF patients
shows excessive TNF-a, LT-a and IL-6 expression (Lesur et al,
1994; Pantelidis et al, 2001) and that the fibrotic response
correlates with B lymphocyte accrual in lungs from non-specific
interstitial pneumonia patients (Keogh & Limper, 2005).
Furthermore, exogenous administration of IL-6 family cytokines
may short-circuit the need for lymphocytes, because in their
absence in Rag1/ mice, Osm can promote lung fibrosis
(Mozaffarian et al, 2008). Indeed, IL6-dependent Stat3 activa-
tion also promotes the production of two other potentialg cascade.
(wt), gp130757F (757F); gp130757F;Il6/ (757F;Il6/) and gp130757F;Stat3þ/
ntrol mice (0). Socs3 signals were normalized to 18S and expressed relative to
as mean SEM with p<0.05 and p<0.01 using Bonferroni multiple
ylated Stat3 (pStat3) of lungs from gp130wt or gp130757F mice 30 days after
l pneumonitis (IPF-UIP) (C). The boxed areas in themiddle panels aremagnified
ith fibrotic areas. Images are representative of three mice and four patients,
panels).
chemical labelled pSTAT3 (red) and pan-cytokeratin (green) or CD45 (green),
&E), ¼20mm (immunofluorescence).
 2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 947
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Figure 6. Stat3 haploinsufficiency prevents lung fibrosis.
A. Masson’s trichrome stained section of lungs for wild-type (wt), Il6/
(Il6/) and Stat3þ/ (Stat3þ/) mice 30 days after saline or bleomycin
treatment. Images are representative of two mice. Scale bar¼ 500mm
(¼ 100mm insets).
B. Percent change in hydroxyproline content in lung homogenates between
saline and bleomycin-treated mice of the indicated genotypes 30 days
after challenge. Data are expressed as mean percentage change SEM,
with p< 0.05. n¼ 5mice. The range of collagen levels between saline and
bleomycin treated mice was 4.442–14.070mg.
948therapeutic targets for bleomycin-induced fibrosis, namely
miR-21 and the generation of IL-17A-producing cells (Liu
et al, 2010; Wilson et al, 2009). Together with our observations
of excessive pSTAT3 accumulation in human IPF biopsies, these
recent findings further strengthen a rationale to exploit Stat3 as
an attractive signalling node for novel therapeutic strategies for
IPF.
Here, we provide genetic evidence for the capacity of Stat3
to link signalling from IL-6 family cytokines to stimulation
of Col1a1 expression and parenchymal collagen deposition 2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.independently of canonical TGF-b/Smad3 signalling. Previous
reports have described the capability of IL-6 to stimulate
collagen deposition in the skin and have identified putative Stat3
binding sites in the Col1a1 and Col3a1 promoters (Lim et al,
2006). Consistent with this, we observed reduced bleomycin-
induced fibrosis in the absence of IL-6 and that gp130-mediated
increase in collagen gene reporter activity in fibroblasts was
dependent on Stat3. By contrast, transgenic expression of IL-6
in the Clara cells of the uninjured mouse lung was associated
with airspace enlargement in older mice (Kuhn et al, 2000),
reminiscent of the distinct emphysematous and inflammatory
changes in lungs of naı¨ve 6 months old gp130757F mice
(Ruwanpura et al, 2011). Although the gp130757F mice used in
this study were less than 3 months old and occasionally showed
mild air space enlargement (Fig 1; Ruwanpura et al, 2011), there
was no evidence for increased IL-6 levels (Fig 2D and Supporting
Information Fig S4A) at this stage. Since IL-6 expression rapidly
increased after bleomycin challenge, we surmise that excessive
IL-6 within the injured lung promotes fibrosis.
Although the development of experimental lung fibrosis
in wild-type mice is inhibited in the absence of canonical
TGF-b/Smad3 signalling (Bonniaud et al, 2004; Zhao et al,
2002), the protective effect arising from its ablation is overcome
in situations of excessive Stat3 activation that results from
mutant gp130757F receptors during bleomycin-induced lung
injury or from the sustained presence of IL-6 family cytokines,
including Osm. Although the inflammatory response elicited
by systemic LPS administration induces the production of the
transcriptionally active Smad2 splice variant Smad2DExon3
(Dunn et al, 2005), which can replicate Smad3 transcriptional
activity (Yagi et al, 1999), it remains unknown whether
Smad2DExon3 can mediate activation of the Col1a1 gene
promoter. Notwithstanding that canonical TGF-b signalling
integrates various inflammatory and regenerative stimuli that
promote wound healing and the deposition of de novo tissue
matrix, our data provide a strong rationale for targeting the
gp130/Stat3 signalling axis as a complementary approach to
current clinical trials focusing on components of the TGF-b
signalling cascade.MATERIALS AND METHODS
Mice and treatments
All mutant gp130DStat and gp130757F mice along with their
corresponding Stat3þ/, Stat1/, Il6/, Rag1/, mMT/ or
Smad3/ counterparts were between the ages of 8 and 12 weeks
and were propagated on a mixed 129/SvC57BL/6 genetic back-
ground (Ehlich et al, 1993; Ernst et al, 2008; Jenkins et al, 2005a;
Tebbutt et al, 2002). All animals were housed under specific pathogen-
free conditions and experimentation was approved by the Institute’s
Animal Ethics Committee.
We transnasally delivered a bolus of 50ml bleomycin (0.05U/mouse;
Blenoxane, Bristol-Myers Squib, New York, USA), or 2mg HYPER-IL-6
every second day for 14 days to anaesthetized mice. We trans-nasally
delivered 5107 PFU adenoviral vector in 30ml PBS and collected
lungs 14 days later (Langdon et al, 2003). Lethally irradiated miceEMBO Mol Med (2012) 4, 939–951
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The paper explained
PROBLEM:
Idiopathic pulmonary fibrosis (IPF) is a heterogeneous disease
with an incidence of approximately 1 per 10,000, equivalent to
many cancers, and which is unresponsive to therapy and fatal in
outcome. Although fibrosis is thought to arise from excessive
tissue response to injury, the molecular mechanisms underlying
the initiation of IPF remain largely unknown.
RESULTS:
In the present study we utilize mutant mice carrying engineered
mutations in gp130, the interleukin (IL)-6 co-receptor, to provide
genetic evidence for the causal involvement of IL-6-dependent
Stat3 signalling in this disease in an established preclinical
setting. Using a genetic complementation approach, we define a
functional requirement for IL-6, Stat3 andmature B-lymphocytes
for the development of disease. Significantly, we provide genetic
and biochemical evidence that Stat3-driven lung fibrosis can
occur by a mechanism independent of signalling through the
canonical transforming growth factor (TGF)-b/Smad3 pathway.
We also document excessive Stat3 activation as a common
feature in human patients with IPF and provide evidence that
reduction of systemic Stat3 expression in mice decreases
susceptibility to bleomycin-induced fibrosis.
IMPACT:
Previous studies have demonstrated that canonical TGF-b/
Smad3 signalling is pivotal to the pathogenesis of pulmonary
fibrosis. Our study demonstrates that that therapeutic targeting
of IL-6/Stat3 signalling and/or B-lymphocytes may ultimately
afford more efficacious treatments for IPF and related diseases
than those directed solely against TGF-b/Smad3 signalling.were reconstituted with bone marrow (Ernst et al, 2008) at least
30 days before challenging with bleomycin. BAL fluid was collected by
endotracheal instillation of three 0.4ml aliquots of PBS to recover
approximately 1ml of fluid, pelleted cells were stained with Quik-Dip
(Scot Scientific, Taren Point, Australia) and differential cell counts
performed.
Cytokines, plasmids and antibodies
The pCol1a1-luc and p(CAGA)12-luc constructs and the production of
HYPER-IL-6 has been described (Buttner et al, 2004; Fischer et al,
1997). Recombinant human IL-6 and human TGF-b1 were from
Bender Medsystems (Vienna, Austria) and Sigma–Aldrich (St Louis,
USA), respectively. Antibodies directed against B220 were from Becton
Dickinson Biosciences (San Jose, USA), CD3 from Serotec (Kidlington,
UK), F4/80 from Abcam (Cambridge, UK), a-tubulin (Sigma–Aldrich),
CD45 and cytokeratin AE1/AE3 from Dako (Glostrup, DK), phosphory-
lated Stat3 (Cell Signaling Technology, Danvers, USA) and b-actin,
Stat3 or phosphorylated Smad3 (Santa Cruz Biotechnology).
Collagen quantification, lung fibroblast preparation and
cellular assays
We analysed hydroxyproline content of lung homogenates as
described (Mutsaers et al, 1998). We digested lungs in 0.25%
trypsin-EDTA (Invitrogen Life Technologies, Carlsbad, USA) at 378C
for 30min and removed remaining connective tissue. Digests were
finely minced and incubated in 1mg/ml collagenase 1 (Invitrogen
Life Technologies) for 1 h at 378C. Pelleted cells were used for
establishing primary lung fibroblast cultures in DMEM (Invitrogen
Life Technologies) supplemented with 10% foetal bovine serum
(Sigma–Aldrich, Castle Hill, Australia), 4mM L-glutamine (Invitrogen
Life Technologies) and penicillin–streptomycin–fungizone cocktail
(Invitrogen Life Technologies), and assays were performed on passage
3–5 cells. We exposed embryonic fibroblasts, co-transfected with
pCol1a1-luc and the pCMV-Rluc plasmid to HYPER-IL-6 andEMBO Mol Med (2012) 4, 939–951determined dual luciferase activity in triplicate cultures 48 h later
(Jenkins et al, 2005a).
RNA isolation and expression analysis
We extracted total RNA from tissues or snap-frozen cell cultures with
TRIzol (Invitrogen Life Technologies) and prepared cDNA from 1mg of
total RNA using the SuperScript III System (Invitrogen Life Technol-
ogies). We performed quantitative RT-PCR analysis on lung tissues in
triplicate with the iCycler platform (Bio-Rad Laboratories, USA) using
SYBR Green (Invitrogen), and quantified Col1a1 (forward 50-GGAA-
GAGCGGAGAGTACTGG-30 , reverse 50-GTACTCG AACGGGAATCCAT-30), Il6
(forward 50-GTATGAACAACGATGATGCACTTG-30 , reverse 50-ATGGTACTC-
CAGAAGACCAGAGGA-30), Il11 (forward 50-CTGCACAGATGAGAGACA
AATTCC-30 , reverse 50-GAAGCTGCAAAGATCCCAATG-30) Osm (forward
50-AACACTGC TCAGTTTGACCCTCAGT-30 , reverse 50-AGGTTTTGGAGGCG-
GATATAGGGCT-30), Socs3 (forward 50-GCGGGCACCTTTCTTATCC-30 ,
reverse 50-TCCCCGACTGGGTCTTGAC-30) transcripts using glyceral-
deyhde-3-phosphate-dehydrogenase (Gapdh) (forward 50-TCGG
TGTGAACGGATTTGGC-30 , reverse 50-GAATTTGCCGTGAGTGGAGT-30) or
18S (forward 50-GTAACCCGTTGAACCCCATT-30 , reverse 50-CCATC-
CAATCGGTAGTAGCG-30) as a housekeeping gene (Scaffidi et al, 2002).
Each RNA sample was analysed in duplicate.
Immunohistochemistry
We stained consecutive 5mm sections of inflated (250mm-H2O
pressure), paraformaldehyde-fixed and paraffin-embedded lungs with
haematoxylin and eosin, Masson’s trichrome (staining collagenous
deposits green), or for the cell lineage markers B220, CD3, F4/80 or
phosphorylated Stat3. We characterized inflammatory foci as a
collection of granulocytic and/or lymphocytic cells that occupied at
least one field of view (20 objective lens), and within these foci
counted the total number of indicated cells from three or more
randomly chosen sections from each tissue block. Paraffin embedded
human tissue was immunolabelled for the cell lineage markers 2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 949
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950pan-cytokeratin, CD45 and phosphorylated STAT3 following antigen
retrieval with 10mM citrate buffer pH6.
Patient samples
Tissue biopsies from four male patients with diagnosed IPF-UIP (age
range of 59–69 years, mean of 63 years) and appropriate controls
were used in this study. Human ethics approval for this study
was provided through Bellberry Limited for work carried out at Sir
Charles Gairdner Hospital, W.A., Australia. All human samples used in
this study were retrospective paraffin embedded tissue samples taken
for diagnostic purposes. The collection and use of these samples for
this study was consistent with Section 3.2.4 of the National Health
and Medical Research Council of Australia, Australian Health Ethics
Committee guidelines for research involving humans and Section 25
of the World Medical Association, Declaration of Helsinki.
Statistical analysis
Data are expressed as mean SEM, with p<0.05, p<0.01,
p<0.001. Statistical analysis was performed using one-way
analysis of variance and Bonferroni’s multiple comparisons post-test.
For more detailed Materials and Methods see the Supporting
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